Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
Pamela C. Proud,
Robert J Watson,
Brendon Y. Chua,
Marilyn J Aram,
Kevin R Bewley,
Breeze E Cavell,
Susan A Fotheringham,
Catherine M K Ho,
Kathryn A Ryan,
Gillian S Slack,
Stephen A. Thomas,
Nadina I Wand,
David C. Jackson,
Nathan W Bartlett,
Miles W Carroll
Posted 25 Sep 2020
bioRxiv DOI: 10.1101/2020.09.25.309914 (published DOI: 10.1016/j.ebiom.2020.103153)
Posted 25 Sep 2020
Respiratory viruses such as coronaviruses represent major ongoing global threats, causing epidemics and pandemics with huge economic burden. Rapid spread of virus through populations poses an enormous challenge for outbreak control. Like all respiratory viruses, the most recent novel human coronavirus SARS-CoV-2, initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat. The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT to reduce SARS-CoV-2 transmission and provide protection against COVID-19. ### Competing Interest Statement The authors have declared no competing interest.
- Downloaded 6,019 times
- Download rankings, all-time:
- Site-wide: 2,667
- In immunology: 104
- Year to date:
- Site-wide: 31,153
- Since beginning of last month:
- Site-wide: 45,154
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!